Literature DB >> 17187139

[Costs and efficacy of type A botulinum toxin for the treatment of essential blepharospasm and hemifacial spasm].

Cintia Gomes Galvão Lasalvia1, Luciano de Sousa Pereira, Marcos Carvalho da Cunha, Silvia Prado Smit Kitadai.   

Abstract

PURPOSE: To evaluate the costs and efficacy of type A botulinum toxin in the treatment of essential blepharospasm and hemifacial spasm.
METHODS: Pacients with essential blepharospasm and hemifacial spasm had their files analyzed. All patients were treated with type A botulinum toxin (Dysport) between April 2002 and May 2004 at the Oculoplastic Clinics of "Santa Casa de São Paulo". Twenty-seven patients presented essential blepharospasm and 23 presented hemifacial spasm. Information about the patient's degree of satisfaction after treatment, complaints and personal costs were recorded by a questionnaire, and information about the costs of Dysport treatment were obtained at the administration department of "Santa Casa de São Paulo". Wilcoxon and Mann-Whitney tests were used for statistical analysis.
RESULTS: 1- The annual treatment costs were R Dollars 1,239.32 for essential blepharospasm and R Dollars 661.72 for hemifacial spasm. 2- The patient's annual costs were R Dollars 145.48 for essential blepharospasm and R Dollars 6.07 for hemifacial spasm. 3- The hospital's annual costs for the treatment were R Dollars 1,095.84 for essential blepharospasm and R Dollars 535.65 for hemifacial spasm. 4- Dysport treatment is successful in both essential blepharospasm and hemifacial spasm.
CONCLUSIONS: The costs of essential blepharospasm and hemifacial spasm treatment with Dysport are high, mainly because of the toxin price. On economic analysis of health, we can conclude that this procedure has an excellent cost-benefit ratio.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17187139     DOI: 10.1590/s0004-27492006000500016

Source DB:  PubMed          Journal:  Arq Bras Oftalmol        ISSN: 0004-2749            Impact factor:   0.872


  1 in total

1.  Botulinum toxin treatment in neurological practice: how much does it really cost? A prospective cost-effectiveness study.

Authors:  Pierre Burbaud; Camille Ducerf; Emmanuelle Cugy; Jean-Louis Dubos; François Muller; Dominique Guehl; Patrick Dehail; Didier Cugy; Nicholas Moore; Alain Lagueny; Pierre-Alain Joseph
Journal:  J Neurol       Date:  2011-03-20       Impact factor: 4.849

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.